Orexigen Therapeutics, Inc.
OREX
OREX was delisted on the 3rd of April, 2018.
27 hedge funds and large institutions have $689K invested in Orexigen Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 16 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
34% less funds holding
Funds holding: 41 → 27 (-14)
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
85% less call options, than puts
Call options by funds: $4K | Put options by funds: $27K
92% less capital invested
Capital invested by funds: $8.79M → $689K (-$8.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$43.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$33.9K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$33.5K |
| 4 |
Citigroup
New York
|
+$19.6K |
| 5 |
Millennium Management
New York
|
+$13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$478K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$429K |
| 3 |
Daiwa Securities Group
Tokyo,
Japan
|
-$418K |
| 4 |
BlackRock
New York
|
-$290K |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$213K |
OREX Hedge Fund Activity: Q1 2018 in Review
27 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q1 2018, worth a combined $689K — down 92% from $8.79M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of OREX and 3 opened new positions — a net loss of 13 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Credit Suisse, adding an estimated $43.3K. The largest seller was NEA Management Company, exiting entirely with an estimated $478K sold.
- 27 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q1 2018, down from 41 in Q4 2017.
- Funds reported $689K of Orexigen Therapeutics, Inc. stock for Q1 2018, down 92% quarter-over-quarter.
- 3 funds opened new Orexigen Therapeutics, Inc. positions in Q1 2018 and 16 closed out, a net change of -13 holders.
- The largest Orexigen Therapeutics, Inc. buyer in Q1 2018 was Credit Suisse, an estimated $43.3K added.
- The largest Orexigen Therapeutics, Inc. seller in Q1 2018 was NEA Management Company, an estimated $478K sold.
Based on aggregated 13F filings for Q1 2018.